NZ598348A - Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels - Google Patents

Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Info

Publication number
NZ598348A
NZ598348A NZ598348A NZ59834810A NZ598348A NZ 598348 A NZ598348 A NZ 598348A NZ 598348 A NZ598348 A NZ 598348A NZ 59834810 A NZ59834810 A NZ 59834810A NZ 598348 A NZ598348 A NZ 598348A
Authority
NZ
New Zealand
Prior art keywords
red blood
blood cell
cell levels
erythropoietin receptor
combined use
Prior art date
Application number
NZ598348A
Other languages
English (en)
Inventor
Jasbir Seehra
Robert Scott Pearsall
Ravindra Kumar
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/583,177 external-priority patent/US8058229B2/en
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority to NZ623113A priority Critical patent/NZ623113A/en
Publication of NZ598348A publication Critical patent/NZ598348A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ598348A 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels NZ598348A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ623113A NZ623113A (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/583,177 US8058229B2 (en) 2008-08-14 2009-08-13 Method of increasing red blood cell levels or treating anemia in a patient
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels
US30590110P 2010-02-18 2010-02-18
PCT/US2010/045509 WO2011020045A1 (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Publications (1)

Publication Number Publication Date
NZ598348A true NZ598348A (en) 2014-05-30

Family

ID=43586530

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ598348A NZ598348A (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
NZ623113A NZ623113A (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
NZ712943A NZ712943A (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ623113A NZ623113A (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
NZ712943A NZ712943A (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Country Status (13)

Country Link
EP (3) EP2464369B1 (enExample)
JP (4) JP5909446B2 (enExample)
KR (5) KR20200124322A (enExample)
CN (7) CN105561295B (enExample)
AU (1) AU2010282361B2 (enExample)
BR (2) BR112012003232B1 (enExample)
CA (1) CA2770822C (enExample)
ES (2) ES2796121T3 (enExample)
IL (6) IL287990B (enExample)
MX (2) MX2012001916A (enExample)
NZ (3) NZ598348A (enExample)
RU (2) RU2642302C1 (enExample)
WO (1) WO2011020045A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
ME00380B (me) 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
EP3520805B1 (en) * 2011-10-17 2021-03-10 Acceleron Pharma Inc. Compositions for treating myelofibrosis
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA2889209C (en) * 2012-10-24 2023-08-22 Celgene Corporation Biomarker for use in treating anemia
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
KR102520970B1 (ko) 2014-03-21 2023-04-12 악셀레론 파마 인코포레이티드 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3212213B1 (en) * 2014-10-30 2021-04-28 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
DK3227675T3 (da) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016128523A1 (en) * 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
DK3286206T3 (da) 2015-04-22 2021-05-03 Biogen Ma Inc Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme
CN108350057A (zh) * 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
EP3370754A4 (en) * 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
US20170240639A1 (en) * 2016-02-22 2017-08-24 Acceleron Pharma Inc. Actrii antagonists for use in increasing immune activity
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
EA201990226A1 (ru) * 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
US11976111B2 (en) 2016-10-05 2024-05-07 Acceleron Pharma Inc. ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
SMT202400437T1 (it) 2017-06-14 2024-11-15 Celgene Corp Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
EP3873441A4 (en) * 2018-12-10 2022-06-29 Arshintseva, Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CN115317589B (zh) * 2022-09-05 2024-12-13 中国海洋大学 脯氨酰羟化酶抑制剂及其应用
CN119198238A (zh) * 2024-09-18 2024-12-27 广东省安家医健健康管理有限公司 一种地中海贫血检测系统及试剂盒

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
ATE352638T1 (de) 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
EP1147413B1 (en) 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CN102526044A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US9682054B2 (en) * 2003-02-07 2017-06-20 Prometic Pharma Smt Limited Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US20070003576A1 (en) * 2004-12-09 2007-01-04 Andrea Gambotto Vaccines for the rapid response to pandemic avian influenza
EP1884235A1 (en) * 2005-04-26 2008-02-06 Ajinomoto Co., Inc. Myeloerythroid progenitor differentiation inducer
JP5361386B2 (ja) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ マトリックスメタロプロテイナーゼ１１ワクチン
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100003190A1 (en) * 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
TW201940502A (zh) * 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN107252486B (zh) * 2008-06-26 2021-10-22 阿塞勒隆制药公司 激活素-actrii的拮抗剂及在提高红细胞水平中的用途
LT3750552T (lt) * 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės

Also Published As

Publication number Publication date
CN105412908B (zh) 2021-08-24
JP2020203953A (ja) 2020-12-24
IL252045B (en) 2020-05-31
IL218052A (en) 2017-05-29
CN113577291A (zh) 2021-11-02
BR112012003232A2 (pt) 2016-11-22
RU2017145301A (ru) 2019-06-24
KR101882521B1 (ko) 2018-07-27
MX2012001916A (es) 2012-05-22
CN113171442A (zh) 2021-07-27
EP2464369A4 (en) 2013-07-17
RU2012109393A (ru) 2013-09-20
NZ623113A (en) 2015-10-30
RU2592670C2 (ru) 2016-07-27
CA2770822C (en) 2020-03-24
AU2010282361B2 (en) 2015-03-19
IL252044A0 (en) 2017-06-29
ES2796121T3 (es) 2020-11-25
IL287990A (en) 2022-01-01
KR102170682B1 (ko) 2020-10-28
IL275851B (en) 2021-12-01
RU2732229C2 (ru) 2020-09-14
CN105561295A (zh) 2016-05-11
NZ712943A (en) 2017-08-25
EP3117829B1 (en) 2020-10-07
CA2770822A1 (en) 2011-02-17
WO2011020045A9 (en) 2011-06-03
MX2019010341A (es) 2019-10-21
KR20230003452A (ko) 2023-01-05
EP3117829A1 (en) 2017-01-18
CN102655872A (zh) 2012-09-05
HK1224199A1 (zh) 2017-08-18
RU2017145301A3 (enExample) 2019-06-24
BR122020019169B1 (pt) 2022-09-27
BR112012003232B1 (pt) 2022-02-22
JP2016034981A (ja) 2016-03-17
KR20180085825A (ko) 2018-07-27
HK1223818A1 (zh) 2017-08-11
KR20190111158A (ko) 2019-10-01
CN113171442B (zh) 2024-11-15
JP5909446B2 (ja) 2016-04-26
IL252044B (en) 2019-11-28
CN105412908A (zh) 2016-03-23
IL252046B (en) 2020-07-30
CN113082194B (zh) 2025-03-18
RU2642302C1 (ru) 2018-01-24
EP2464369A1 (en) 2012-06-20
WO2011020045A1 (en) 2011-02-17
IL218052A0 (en) 2012-04-30
KR20200124322A (ko) 2020-11-02
CN105535938A (zh) 2016-05-04
CN113082194A (zh) 2021-07-09
CN105561295B (zh) 2020-03-20
JP2013501816A (ja) 2013-01-17
IL252045A0 (en) 2017-06-29
IL275851A (en) 2020-08-31
JP6860533B2 (ja) 2021-04-14
JP2018177816A (ja) 2018-11-15
CN102655872B (zh) 2016-01-20
ES2844123T3 (es) 2021-07-21
KR20120054024A (ko) 2012-05-29
KR102606494B1 (ko) 2023-11-24
IL287990B (en) 2022-07-01
EP3838919A1 (en) 2021-06-23
CN105535938B (zh) 2022-04-26
EP2464369B1 (en) 2020-03-11
AU2010282361A1 (en) 2012-03-15
RU2020127574A (ru) 2022-02-21
IL252046A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
NZ603200A (en) Peptides and their use
NZ608502A (en) Polypeptides that bind to human complement component c5
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2012041342A5 (enExample)
SG10201908848RA (en) Pharmacologically induced transgene ablation system
MX2011013126A (es) Alimentos medicos con glicomacropeptido para el manejo nutricional de fenilcetonuria y otros trastornos metabolicos.
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
MX343802B (es) Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP2015518485A5 (enExample)
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
NZ603028A (en) Tfpi inhibitors and methods of use
NZ610620A (en) Inhibitors of apoptosis and uses thereof
MX352796B (es) Proteina de fusion anticancerigena.
WO2012064709A3 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
CA2504377A1 (en) Pharmaceutical preparation of recombinant factor viii lyophilized without albumin as a stabilizer
GEP20156332B (en) Pyrazoles as crth2 antagonists
MX343784B (es) Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 AUG 2017 BY SHELSTON IP

Effective date: 20140902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2018 BY COMPUTER PACKAGES INC

Effective date: 20170718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2019 BY COMPUTER PACKAGES INC

Effective date: 20180718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2020 BY COMPUTER PACKAGES INC

Effective date: 20190718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2021 BY COMPUTER PACKAGES INC

Effective date: 20200718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2022 BY IPAN GMBH

Effective date: 20210730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2023 BY THOMSON REUTERS

Effective date: 20220704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2024 BY THOMSON REUTERS

Effective date: 20230703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2025 BY THOMSON REUTERS

Effective date: 20240702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2026 BY THOMSON REUTERS

Effective date: 20250701